NCT00775905已完成不适用
The Objective of This Study Was to Compare the Rate and Extent of Absorption of Ranbaxy Amlodipine 10 mg Tablet to That of Norvasc® 10 mg Tablet After a Single, One Tablet Dose in Fasted Subjects.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Bioequivalence
研究概览
简要总结
The objective of this study was to compare the rate and extent of absorption of Ranbaxy amlodipine 10 mg tablet to that of Norvasc® 10 mg tablet after a single, one4ablet dose in fasted subjects.
详细描述
The study was conducted as an open label, balanced, randomised, two-treatment, two-period, two-sequence, single-dose, crossover , bioequivalence study on Amlodipine besylate formulations comparing Amlodipine 10mg tablets of Ranbaxy Laboratories with (Norvasc®, Pfizer Inc USA, in healthy, adult, human, subjects under fasting conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Is the individual a healthy, normal adult man and woman who volunteers to participate? ls s/he at least 18 years of age? Is his/her BMI between 19 and 30, inclusive? Is she willing .to avoid pregnancy by abstaining from sexual intercourse with a non-sterile male partner, or by the use one of the following methods: diaphragm + spermicide or condom + spermicide (at least 14 days before dosing), intra- uterine contraceptive device or hormonal contraceptives (at least 4 weeks prior to dosing), or has she been surgically sterile or post-menopausal at least six months prior to entering into the stndy?
- •Is s/he considered .reliable and capable of understanding his/her responsibility and role in the study.
- •Has s/he provided written informed consent?
- •A no answer to any of the above questions indicated that the individual was ineligible for enrollment
排除标准
- •Does the individual have a history of allergy or hypersensitivity to amlodipine? Does s/he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
- •Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interfere with the conduct or interpretation of the study or jeopardize his/her safety'?
- •Is she nursing?
- •Does s/he have serious psychological illness?
- •Does s/he have significant h/story (within the past year) or clinical evidence of alcohol or drug abuse? •
- •Does s/he have a positive urine drug screen or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test? Has s/he consumed grapefruit or grapefruit juice during the 7rday period preceding study initiation?
- •Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken in each study period?
- •Has s/he used any prescription drug, other than hormonal contraceptives, during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation?
- •Is s/he unable to refrain from the use of all concomitant medications, other than hormonal contraceptives, during the study?
- •Has s/he donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation?
- •Has s/he donated plasma during the two week period preceding study initiation? Has s/he received an investigational drug during the 30 day period preceding study initiation? Is s/he a heavy smoker (usually smoking more than 10 cigarettes per day)?
研究组 & 干预措施
1
Experimental
amlodipine 10 mg tablets of Ranbaxy
干预措施: amlodipine 10 mg tablet (Drug)
2
Active Comparator
Norvasc® 10 mg tablets
干预措施: amlodipine 10 mg tablet (Drug)
结局指标
主要结局
Bioequivalence
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Bioequivalence Study of Amlodipine 10mg Tablets Under Fed ConditionsHealthyNCT00775151Ranbaxy Laboratories Limited40
已完成
1 期
Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting ConditionsHealthyNCT00834977Teva Pharmaceuticals USA48
已完成
1 期
Amlodipine 10 mg Tablets Under Fed ConditionsHealthyNCT00841815Teva Pharmaceuticals USA28
已完成
1 期
Bioequivalency Study of Ranitidine Tablets 300 mg of Dr. Reddy's Under Fasting ConditionsHealthyNCT01131702Dr. Reddy's Laboratories Limited24
已完成
1 期
Ramipril 10 mg Capsule in Healthy Subjects Under Fasting ConditionsHealthyNCT00829452Teva Pharmaceuticals USA40